Summary

Eligibility
for people ages 21 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
estimated completion

Description

Summary

This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.

Details

PRIMARY OBJECTIVES: I. Greater intervention effects on health-related quality of life SECONDARY OBJECTIVES: I. Greater intervention effects on patient activation II. Greater satisfaction with care and decision-making III. Greater documentation of goals of care and symptoms IV. To lower acute care V. Greater palliative care and hospice OUTLINE: Sites are randomized to 1 of 2 arms. ARM A: Patients receive educational materials to assist with advance care planning and symptom management through a technology-based supportive cancer care weekly during months 1-4 and every other week during months 5-12. ARM B: Patients are paired with a lay health worker who will discuss the same educational materials from ARM A either in person or by telephone discussions weekly during months 1-4 and every other week during months 5-12. All participants complete a baseline interview upon enrollment during the initial consent phone contact and then a survey at 3-, 6-and 12-months post enrollment.

Keywords

End of Life, Cancer, Carcinoma, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Sarcoma, Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Stomach Neoplasms, Glioblastoma, Rectal Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Skin Neoplasms, Small Cell Lung Carcinoma, Osteosarcoma, Myelodysplastic Syndromes, Disease Progression, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Diseases, Urogenital Neoplasms, Carcinoma, Bronchogenic, Death, Receive technology-based supportive cancer care, Receive redesigned team-based supportive cancer care

Eligibility

You can join if…

Open to people ages 21 years and up

  1. Newly diagnosed patients with a solid tumor cancer diagnosis or hematologic malignancy
  2. Patients must have the ability to understand and willingness to provide consent
  3. Participants must speak English or Spanish

You CAN'T join if...

  1. Inability to consent to the study
  2. Plans to change oncologist within 12 months
  3. Employed by the practice site
  4. Patients who anticipate moving from the area within 12 months

Locations

  • Zuckerberg San Francisco General not yet accepting patients
    San Francisco California 94110 United States
  • San Francisco VA Medical Center accepting new patients
    San Francisco California 94121 United States
  • Kaiser Foundation Research Institute not yet accepting patients
    San Francisco California 94115 United States
  • University of San Francisco not yet accepting patients
    San Francisco California 94117 United States
  • VA Medical Center, Fresno accepting new patients
    Fresno California 93703 United States
  • VA Palo Alto accepting new patients
    Palo Alto California 94305 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Stanford University
ID
NCT05297734
Study Type
Interventional
Participants
Expecting 2996 study participants
Last Updated